Natera to Present 12 Datasets Featuring Over 50,000 Patients at SABCS 2025

Natera will present 12 abstracts at the San Antonio Breast Cancer Symposium featuring data from over 50,000 patients using Signatera, a genome-based test for breast cancer recurrence. The data demonstrates 100% sensitivity and specificity in detecting breast cancer recurrence in the surveillance setting, with patients who tested positive for Signatera at any time post-treatment associated with worse distant recurrence-free survival. The presentations showcase the prognostic and predictive power of Signatera across diverse breast cancer subtypes and settings.